Literature DB >> 22302637

Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels.

Ramya Thota1, Apar Kishor Ganti, Shanmuga Subbiah.   

Abstract

Heparin resistance (HR) is defined as increasing requirements of heparin to maintain a therapeutic activated partial thromboplastin time (aPTT). It is commonly associated with antithrombin deficiency, increased heparin clearance and elevations in heparin binding proteins. Elevated factor VIII levels can cause decrease the aPTT levels (anticoagulant effect) without disturbing heparin activity measured by anti-Xa assay (antithrombotic effect) leading to an apparent heparin resistant state rather than a true heparin resistance. We highlight the importance of increasing awareness of apparent HR and early distinction from true resistance to avoid major life threatening hemorrhagic complications. We hereby report an unusual case of heparin resistance due to increased factor VIII levels in an elderly male with infective endocarditis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302637     DOI: 10.1007/s11239-012-0692-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

1.  Apparent heparin resistance from elevated factor VIII during pregnancy.

Authors:  R A Raschke; J R Guidry; M R Foley
Journal:  Obstet Gynecol       Date:  2000-11       Impact factor: 7.661

2.  Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.

Authors:  F D Cirisano; S Lee; J S Greenspoon
Journal:  J Reprod Med       Date:  1996-03       Impact factor: 0.142

Review 3.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.

Authors:  J D Olson; C F Arkin; J T Brandt; M T Cunningham; A Giles; J A Koepke; D L Witte
Journal:  Arch Pathol Lab Med       Date:  1998-09       Impact factor: 5.534

4.  Monitoring heparin anticoagulation in the acute phase response.

Authors:  James Uprichard; Richard A Manning; Michael A Laffan
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

5.  Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.

Authors:  R A Esposito; A T Culliford; S B Colvin; S J Thomas; H Lackner; F C Spencer
Journal:  J Thorac Cardiovasc Surg       Date:  1983-03       Impact factor: 5.209

6.  Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis.

Authors:  H M Chiu; J Hirsh; W L Yung; E Regoeczi; M Gent
Journal:  Blood       Date:  1977-02       Impact factor: 22.113

Review 7.  Treating heparin resistance with antithrombin or fresh frozen plasma.

Authors:  Bruce D Spiess
Journal:  Ann Thorac Surg       Date:  2008-06       Impact factor: 4.330

8.  Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting.

Authors:  G M Cloyd; M N D'Ambra; C W Akins
Journal:  J Thorac Cardiovasc Surg       Date:  1987-10       Impact factor: 5.209

9.  A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

Authors:  M N Levine; J Hirsh; M Gent; A G Turpie; M Cruickshank; J Weitz; D Anderson; M Johnson
Journal:  Arch Intern Med       Date:  1994-01-10

10.  Heparin binding to plasma proteins, an important mechanism for heparin resistance.

Authors:  E Young; M Prins; M N Levine; J Hirsh
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

View more
  2 in total

1.  Elevated Factor VIII Levels Associated with Acute Graft Occlusion and Arterial and Venous Thrombosis After Off Pump CABG.

Authors:  Crystal A Kyaw; Pey-Jen Yu; Frank Manetta
Journal:  Int J Angiol       Date:  2015-07-31

2.  Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.

Authors:  Robert Beun; Nuray Kusadasi; Maaike Sikma; Jan Westerink; Albert Huisman
Journal:  Int J Lab Hematol       Date:  2020-06       Impact factor: 2.877

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.